Print Page  |  Contact Us  |  Report Abuse  |  Sign In  |  Join ACAM
ACAM Integrative Medicine Blog
Blog Home All Blogs
Search all posts for:   

 

View all (301) posts »
 

A Comprehensive Review of the Safety and Efficacy of Bioidentical Hormones

Posted By Deborah Moskowit, ND, Thursday, August 11, 2011
Updated: Thursday, January 30, 2014

Abstract

Numerous forms of estrogens and progestins are utilized for the treatment of menopausal complaints and associated conditions that occur temporally. Although known to be different with respect to molecular structure, receptor affinity, metabolism, and other physiological traits, most have been treated as if they were clinically identical. The majority of these hormone preparations, commonly referred to as hormone replacement therapy (HRT), should perhaps be more aptly referred to as hormone substitution therapy, as most of the therapies utilized do not exactly match those produced in the body.Research indicates these synthetic hormones vary clinically in safety and efficacy. As such,women and their physicians have, in increasing numbers, been opting for the use of bioidentical hormones; i.e., those that match the structure and function of hormones produced in the body.With greater utilization and research surrounding bioidentical hormones, the differences can now begin to be fully assessed and appreciated. This article reviews the disparities between synthetic and bioidentical estrogens and progestins/progesterone with respect to safety and efficacy;special attention is devoted to clinical outcomes in the breast, endometrium, bone, cardiovascular system, and brain. The studies reviewed suggest bioidentical progesterone does not have a negative effect on blood lipids or vasculature as do many synthetic progestins, and may carry less risk with respect to breast cancer incidence. Studies of both bioidentical estrogens and progesterone suggest a reduced risk of blood clots compared to nonbioidentical preparations. Bioidentical hormone preparations have demonstrated effectiveness in addressing menopausal symptoms. The author advocates for continued research on bioidentical hormones and concludes there is  currently sufficient evidence to support their preferred use over that of their synthetic cousins.(Altern Med Rev 2006;11(3):208-223)

Introduction

Over the last decade, women and their physicians have in increasing numbers been opting for the use of natural, bioidentical hormones for treatment of symptoms of menopause and to support bone and heart health. (1) The trend away from the use of conventional synthetic hormones, toward those specifically matching the hormones produced in humans (bioidentical)has been driven by several factors, including a global trend toward everything "natural” as seen in the increased interest in organic foods and complementary and alternative medicine (CAM). Perhaps the most significant factor driving the increased interest in bioidentical hormones is the rising fear or suspicion of the "synthetic” hormones used in conventional hormone replacement therapy (HRT). Over the last decade, research-based media reports of risks associated with conventional HRT have prompted women’s concerns and altered the approach to hormone use. (2,3) This has been most evident following the results of the U.S. government-sponsored Women’s Health Initiative (WHI) study in 2002. The WHI study results led to the conclusion of experts in the field that the risk of using conventional HRT (non-bioidentical hormones), specifically Premarin®and Provera®, outweighed the benefits provided. (4) This report was followed by a significant decline in the use of synthetic hormones at menopause, and a growing number of women and their physicians utilizing and advocating the use of bioidentical hormones. The question, without the value of a similar long-term study looking at bioidentical hormones, is whether or not the evidence exists to support their preferred use over their synthetic cousins.

Hormone Changes Surrounding Natural (Non-induced) Menopause

Menopause is defined as the cessation of menstruation occurring as a result of the loss of ovarian follicular activity. At birth, a woman has a million eggs, by puberty a mere 300,000. This loss of eggs is referred to as atresia, a natural, albeit incompletely understood, process whereby the follicles enter an incomplete growth phase. This process continues throughout a woman’s life. Thousands of follicles are lost to atresia compared to one or a few lost each month to ovulation. As a woman ages and as a result of the decreasing follicles, follicle-stimulating hormone (FSH) levels gradually increase and the cycle begins to shift, with a shortening of the follicular phase that can begin as early as a woman’s 20s. (5,6) In the 10-15 years prior to menopause, this rate of follicular atresia begins to accelerate. (7,8) Perimenopause is the term used to describe the time of transition between a woman’s reproductive years and cessation of menstruation. Typically perimenopause occurs between the ages of 40 and 51 and can last anywhere from six months to 10 years. During this time, hormone levels fluctuate and decline naturally, although not necessarily in an orderly manner.

Perimenopause often begins with an alteration in cycle and bleeding regularity due to fluctuatin ghormones, anovulatory cycles, and changes in timing of ovulation. Cycles may be long or short, ovulatory or anovulatory. (8) Even women who cycle regularly during perimenopause can have significant variability in hormone levels. (7) Progesterone levels drop with anovulatory cycles and a decline in luteal function.Estrogen levels fluctuate in response to rising FSHlevels and provide feedback inhibition to FSH. (6) Significant variability may occur in estradiol and inhibin (a hormone that inhibits FSH), and gonadotropins may rise abruptly. (5,6,9) Testosterone levels decline with age and do not appear to change significantly with natural menopause. By menopause, few follicles remain, yet intermittent estradiol production from the ovaries may still occur. (8,9) Adrenal androstenedione is the primary source of estrogen after menopause; sex hormone-binding globulin falls slightly. (10) FSH levels remain high for several years after menopause, after which levels decline considerably. (10,11)

Although FSH is commonly used, there are no consistently reliable endocrine markers to establish a woman’s menopausal status. (9) Shifts in hormones contribute significantly to a sense of physical,mental, and emotional imbalance that may characterize a woman’s experience of menopause. As a clinician, it is important to note the changes that occur,link them to the physiology of the various hormones,and address imbalances individually. Addressing other aspects of endocrine health is also necessary and may involve assessing adrenal and liver function, as well as diet, exercise, and other lifestyle factors.

Problems with Conventional HRT

In July 2002, after determining that estrogen in combination with progestin increased a woman’s risk of breast cancer, coronary events, stroke, and blood clots, the National Institutes of Health (NIH)prematurely halted the first part of the WHI, a study designed to identify the risks and benefits associated with long-term hormone use. In this study, 16,608healthy postmenopausal women with a uterus, ages50-79, were randomized to either test or placebo group. (4) The test group received a combination of equine estrogen and synthetic progestin (PremPro®);no bioidentical hormones were used. At the time the study was halted, PremPro compared to placebo resulted in:

  • t26-percent increased risk of invasive breast cancer (eight additional cases per 10,000 women per year);
  • t29-percent increased risk of myocardial infarction (MI) or death from coronary heart disease (CHD) (seven additional cases per 10,000 women per year);
  • t41-percent increased risk of stroke (eight additional cases per 10,000 women per year);and
  • t200-percent increased risk of blood clots (18 additional cases per 10,000 women per year).
  • The WHI study also confirmed benefits seen in previous studies, most notably:
  • t33-percent decreased risk of hip fracture (five fewer fractures per 10,000 women per year);
  • t37-percent decreased risk of colorectal cancer (six fewer cases per 10,000 women per year); and
  • tRelief of menopausal symptoms like hot flashes and vaginal atrophy.

An ancillary study the following year, the Women’s Health Initiative Memory Study (WHIMS),demonstrated additional risks for women on combination equine estrogens and synthetic progestins. The study found combination therapy doubled the risk of developing dementia in women age 65 and older. (12)

Even prior to the WHI and WHIMS studies,relatively few women who might benefit from HRT chose to use it, despite the previous findings that HRT has established benefits for the treatment of menopausal complaints, reduction in bone loss, and some beneficial effects on the cardiovascular system. (13-15) In addition, women prescribed HRT often discontinue it before long-term benefits are realized. The most common reasons for discontinuation of HRT are unwanted side effects and weight gain, with one-third to two-thirds of women discontinuing it within the first two years. (13,14,16-18) Most side effects are attributed to the synthetic progestin portion of HRT, with the most common complaints being bloating, breast tenderness, and irregular bleeding. (13,14,19) Secondary reasons for discontinuation include fear of cancer and recommendation by a physician.

For women not initiating HRT, reasons cited include: HRT perceived as unnecessary, a preference to not take medications, a fear of the effects of long-term HRT, confusion over the scientific information as presented in the media, and the view that menopause is a natural event. (2,3,14,20) Use of HRT was correlated with older women’s wishes to reduce osteoporosis risk, while younger women sought relief from menopausal symptoms, predominantly vasomotor flushing. (2,19) Given this information, it should follow that utilizing hormones that have fewer side effects andrisks, correlate with a woman’s perception of "natural,” and address long-term health benefits could increase hormone use and therefore improve a woman’shealth and well-being. Bioidentical hormones mayprovide these benefits.

What is Bioidentical HormoneTherapy?

Bioidentical hormones are identical to hormones produced endogenously. In the case of HRT,these include estrone (E1), estradiol (E2), estriol(E3), and progesterone (P4). Although bioidenticalhormones have long been utilized in other countries,the United States has predominantly used non-bioidentical hormones for the past 40-45 years, beginning with the introduction of oral contraceptives inthe early 1960s.

The differences in the actions, risks, and benefits of various hormones depend on numerous factors, including method of administration, absorption,bioavailability, metabolism, receptor affinity, receptor specificity, and molecular structure. (21,22)

Bioidentical versus SyntheticEstrogens

The body naturally produces three mainforms of estrogen: estrone, estradiol, and estriol. Bioidentical estrogens are molecularly identical to these naturally produced estrogens. Synthesized in the ovaries and metabolized in the liver, estradiol is the mostphysiologically active form of estrogen. Increased serum estradiol levels are linked to an increased risk ofbreast and endometrial cancer. (23) Estrone is converted reversibly from estradiol in the liver and small intestine and increases after menopause when the adrenalglands play a more prominent role than the ovaries inhormone synthesis. Like estradiol, increased estronelevels are linked to an increased risk of estrogen-receptor positive (ER+) breast cancer and an increase in breast density, an independent risk factor for breast

Table 1. Synthetic and Bioidentical Estrogen Preparations Available in the United States

Table1
Table 2. Synthetic Progestin and Bioidentical Progesterone Preparations Available in the United States

Table2
cancer. (24,25) Both estradiol and estrone can be metabolized to estriol, which is the primary urinary metabolite. Estriol is considered the "weakest” estrogen, as it has a shorter-acting effect than estradiol or estrone. (26) However, depending on sufficient dosing and route of application, estriol can attain a full estrogenic effecton target tissue, such as the vaginal mucosa. (26) Estriolremains intact when supplemented orally (i.e., unlike estradiol, estriol is not converted to estrone, nor is it converted to estradiol). (27) In Europe and China, estriolis commonly used for HRT. A comprehensive review of the safety and efficacy of estriol suggests it maybe safer than estrone or estradiol, but can still have a stimulatory action on the endometrium and breastwhen given in high doses. (28)

In a comparison of bioidentical (estropipate,estradiol) versus non-bioidentical estrogens (ethinylestradiol, conjugated equine estrogens, diethylstilbestrol), non-bioidentical estrogens had significantly exaggerated responses across multiple hepatic and non-hepatic measures of estrogenic effects. (29)

The predominant estrogen currently prescribed in the United States is Premarin, a brand name for conjugated equine estrogens (CEE). Premarincontains approximately 100 distinctly different estrogens, mainly estrone sulfate, equilins, equilenins, and alpha-estradiol, all of which are estrogens occurring naturally in horses; with few natural to the human body. Over 30-percent drop in sales revenues from both Premarin and PremPro occurred following reports of the WHI study. (30)

Many estrogen formulations presently available in the United States contain bioidentical estrogens (Table 1). A growing number of conventional and CAM physicians are now prescribing "Tri-Est,”or "Bi-Est,” nicknames given to individually-compounded formulations of estriol, estrone and estradiol, or estriol and estradiol, respectively. Licensed pharmacists can fill a doctor’s prescription for these combinations of natural estrogens in a variety of doses and delivery systems to specifically address patient needs.

Natural Progesterone versus Synthetic Progestins

Inconsistency in use of the terms "progesterone,” "progestin,” and "progestogen” has led to confusion over these substances. Progesterone refers to a single (note the "one” at the end of the term)molecular structure that is identical to the progesterone molecule that the body makes, also referred to biochemically as "P4.” Progestogen is the category of hormone molecules (natural and synthetic) that act like progesterone in the uterus. Progestin generally refers to synthetic progestogens. See Table 2 for a list of commonly prescribed progestogens.

Progesterone was originally procured by extraction methods from animal placenta. Natural progesterone products today are produced in a laboratory setting via a process designated as the "Marker Degradation” from saponins found in soy and Dioscoreavillosa (wild yam). Hudson presents a detailed historic perspective of the series of events surrounding the discovery of this process. (31)

Progesterone was first used as HRT in 1934for the treatment of ovariectomized women. (32) Due to significant first-pass effect of progesterone, synthetic progestins were developed in the 1940s, either fromprogesterone (e.g., medroxyprogesterone acetate) or from testosterone (e.g., 19-nortestosterone). (33) Progestins mimic the body’s progesterone closely enough to bind to progesterone receptor sites, but do not deliver the full range of "messages” a natural progesterone molecule does. A synthetic progestin, for example,may have similar effects on the endometrium, yet can initiate widely different actions elsewhere in the body (e.g., brain, mineralocorticoid receptors, etc.)depending on the classification of the particular progestin (nortestosterone derivatives, ethyl-13 derivatives, progesterone derivatives, or norprogesterone derivatives.) (34,35) These different progestins have been mapped as to affinity to androgen, progesterone,glucocorticoid, and estrogen receptors. (36) In contrast to progesterone, 19-nortestosterone derivatives are known to have estrogenic properties, which could be attributed to their estrane structure (an 18-carbon tetracyclic hydrocarbon nucleus that is the parent structure to all estrogens) or to the production of estrogenas a metabolite. (37) Derivatives of 19-nortestosteronehave been shown to increase the growth of ER+breast cancer cells in vitro. (38) A paper published in 2000 discussed the development of newer synthetic progestins that more closely fit the profile of bioidentical progesterone. (39)

Estrogen, Progesterone, or Both?

Current recommendations from the American College of Obstetricians and Gynecologists suggest that estrogens be prescribed in conjunction with progestins (to prevent endometrial hyperplasia) when a woman has an intact uterus; (40) conversely, unopposed estrogens are the norm post-hysterectomy. Although progesterone and estrogen receptors both exist in tissue outside the uterus, it has not been thought necessary to provide progestins after the uterus is removed.

In contrast, when using natural hormones,many physicians consider the concomitant use of progesterone with estrogen to be an important aspect of bioidentical hormone therapy and hormonal balancing. The growing research on the synergism of thesetwo hormones, as well as an expanded understanding of progesterone’s effect in the body, are prompting some to recommend these hormones be prescribed together, regardless of the presence or absence of auterus. (41,42)

When considering estrogen replacement during perimenopause and early menopause, thelevel of endogenous estrogen production must also be considered, since elevated FSH levels can be associated with either increased or decreased levels of estrogen. (9,11) Since progesterone levels can fall first with the advent of an ovulatory cycles, some women may do well with progesterone-only supplementation during perimenopause, which may help balance the effects of unopposed endogenous estrogen production. FSH, although commonly used as a diagnostic indicator of menopause, may not be the most reliable tool for determining estrogen needs perimenopausally. (9) One should also note that women with a greater amount of body fat can produce a significant amount of endogenous estrogen postmenopausally. This can occur exclusively through aromatization of estrogen sfrom adrenal and rostenedione by the fat cells. (10) In one study, 10-15 percent of postmenopausal women produced enough estrogen to build the endometrial lining, further emphasizing the need to determine individually the potential hormonal needs of each woman during the climacteric.

Hormone Synergy

Hormone function can be affected by the presence of other hormones, as is seen in the synergistic effects of E2 and P4. (41,43) Even the receptors can exhibit synergism, although the exact mechanisms have not been fully elucidated. (44,45) An example of this phenomenon in clinical practice is the synergistic antiovulatory effects of estrogen and progestogens resulting in efficacy of lower-dose oral contraceptives equal to that of higher-dose regimens. More recently,a study found estradiol in combination with progesterone inhibited bone resorption to a greater degree than either hormone alone. (46)

Differences in Hormone Delivery

Continuous versus Pulsed Delivery

There is sufficient evidence to suggest the pulsatile delivery of estrogen and progesterone that occurs naturally serves to enhance the functioning of these hormones in the body. (47-49) In theory, continuous application of hormones may serve to down-regulate receptors, contributing to a general decrease in the activity of those particular hormones. Research has demonstrated that sequential pulsed estrogen and progestin therapy allows for smaller amounts of hormones to be used. (47) Reduced dosage would translate to reduced likelihood of unwanted side effects as well as a reduced impact on the liver via metabolism of supplemented hormones. This also supports the most recent U.S. Food and Drug Administration recommendation surrounding hormone therapy for women that advocates using the lowest effective dose for the least amount of time necessary. (50)

Routes of Administration

Many different routes of delivery are available for natural hormones, including oral, transdermal (patch), percutaneous (cream, gel), intramuscular(IM), subcutaneous, sublingual, vaginal (gels, cream,tablet, ring, and pessary), and nasal. The route of administration can confer differences in absorption,metabolic pathway, and bioavailability. In general,the oral route leads to more rapid metabolism and a greater impact on hepatic processes, requiring larger doses than those bypassing the entero-hepatic circulation. The same sized doses of progesterone and estradiol resulted in greater circulating blood levels when delivered vaginally compared to oral administration, due to entero-hepatic metabolism. (51) In comparing different E2 delivery systems, percutaneous, transdermal, and vaginal delivery resulted in a reduction in metabolism to E1 via the entero-hepatic circulation. (51-53) Side effects common with oral E2 were not seen when administration was via the percutaneous or transdermal routes. (54,55)

Approximately 90 percent of oral progesterone is metabolized by the "first pass effect” (caused by shunting through the entero-hepatic circulation),leading to difficulties in dosing as well as an abrupt increase in 5-alpha-progesterone metabolites. (56) Oralprogesterone administration resulted in higher levels of progesterone metabolites (deoxycorticosterone, deoxycorticosterone sulfate, and 5-alpha and betapregnenolone) when compared to vaginal administration. (51-57) A study by Hermann et al compared 80 mg progesterone daily via a topical cream (Pro-Gest®)to 200 mg oral micronized progesterone (OMP) as Prometrium®daily and found no difference between the two products with respect to steady-state blood levels of progesterone as measured by area under thecurve (AUC). (58) In another comparison study, similar endpoints were achieved with 300 mg oral micronized progesterone and 90 mg vaginal progesterone,with fewer side effects of drowsiness noted with the vaginal application (an effect attributed to 5-alphaand beta metabolites of progesterone). (59)

It is important to note that progesterone and its metabolites have differing effects in the brain,uterus, smooth muscle, and oocyte. (60) For example,depressive effects of progesterone are predominantly attributed to pregnane metabolites, such as allopregnanolone, as opposed to progesterone itself. Given the increase in metabolites seen with OMP, vaginalor topical delivery systems may reduce expression of side effects attributed to these metabolites.

Because numerous factors can influence intestinal absorption and metabolism, some preparations may have more variable effects. In a study of the pharmacokinetics of oral versus IM administration ofE2, 4 mg IM demonstrated a rate of release into the bloodstream that achieved therapeutic levels over 2-4weeks (depot effect). To achieve the same therapeutic equivalency with an oral dose, some individuals required as much as 2 mg daily for three weeks. (61)

Oral micronized progesterone also exhibits substantial variability in absorption among individuals. In one study, maximum serum concentration ranged from 15.72-625.98 ng/mL, following a single300 mg dose; the authors also noted that absorption increased with age. (62) In a separate study of percutaneous absorption of a progesterone cream, the authors reported moderate variability among individuals. (63)

Forms of Administration

The base of a cream, gel, or suppository can also affect absorption. In a study of topical applications comparing progesterone in a hydrophilic gel, lipophilic base, and emulsion-type base, (64) the emulsion-type base led to a two-fold greater AUC and peak plasma concentration than either the hydrophilicgel or lipophilic base. (64) Another study by the same authors comparing two suppository bases found anemulsion-type base resulted in improved pharmaceutical availability when compared to a lipophilic baseof cocoa butter. (65) A comparison between the percutaneous and vaginal delivery systems found the elimination half-life for the three transdermal forms ofprogesterone was in the range of 30-40 hours, (64) compared to the cocoa butter vaginal suppository with anelimination half-life of 9-10 hours and the emulsionbased suppository with an average elimination halflife of 14 hours. (65)

Physiological levels of serum progesteronewere reached via a novel nasal spray application. (66) Also unique is an effervescent progesterone vaginaltablet that results in adequate serum progesterone levels. In this study there was significant age-related difference in time of maximum concentration (Tmax),with women over 40 years attaining a lower Tmaxthan younger women. (67)

Given the differences that abound in both thetype and route for administration of hormones, physicians should assess an individual woman’s need forhormone therapy and tailor the regimen to her needs.

Effect of Hormones on theCardiovascular and EndocrineSystems

Hormones have multiple effects on the cardiovascular and endocrine systems, including eliciting actions on blood pressure, vascular tone, hemostasis, lipid metabolism, cardiac vasospasm, andglucose metabolism.

Blood Pressure Effects

Progesterone antagonizes mineralocorticoidssuch as aldosterone. Since aldosterone enhances sodium retention and potassium loss via the urine, antagonism of this effect results in increased sodiumexcretion in the urine. This effect on sodium loss hasbeen shown to reduce blood pressure in hypertensivepatients in some studies, as well as ease symptoms ofwater retention. (68,69) This anti-mineralocorticoid effectis not seen with the majority of available syntheticprogestins. Moreover, some progestins enhance estrogen activity, contributing to the potential for increased blood pressure. (70,71)

In normotensive patients, progesterone candecrease sympathetic vascular tone, without concomitant drop in blood pressure. (72) Progesterone acts viathe nitric oxide pathway to enhance vasodilation andimprove microcirculation. (73,74) In animal studies, endogenous and low-dose parenteral E2 have also beenshown to increase vasodilation. (70)

Blood Clots

Estrogen replacement therapy is known toincrease the risk of blood clots. High-dose estrogens,especially synthetic and oral estrogens, increase liverprotein synthesis, including coagulation factors. Oralestrogens also increase angiotensin, and may raiseblood pressure and stroke risk in susceptible women. (70) In a randomized crossover study, estriol did notaffect hemostatic function, whereas ethinyl estradioldecreased prothrombin time while increasing plasminogen and factor VII. (75) In the WHI study, CEEwith medroxyprogesterone acetate (MPA) was shownto increase blood-clotting events. (76)

In contrast to synthetic hormone use, a recentstudy evaluating progesterone cream for safety andefficacy found no markers for inflammation or clotting. (77) The study also found that in women with higher than normal cortisol levels, there was a marked decline in the level of cortisol to the normal range whileusing progesterone cream compared to placebo. (77)

Hormone Effects on Lipids,Atherosclerosis, Vasospasm, and InsulinResistance

Activated by stress, increased cortisol hasbeen associated with an increased risk of atherosclerosis, obesity, and other manifestations of heart disease. Cortisol can contribute to atherosclerosis by increasing cholesterol ester formation. While estrogenwas seen to have no effect on cholesterol esters, progesterone blocked cholesterol ester formation, signifying an anti-atherogenic effect of progesterone. (78)

Whereas some synthetic progestins areknown to exert a negative effect on blood lipids, bioidentical progesterone does not appear to do so. (79,80) Inthe Postmenopausal Estrogen and Progestin Interventions (PEPI) Trial, oral micronized progesterone faredsignificantly better than MPA, as OMP did not bluntthe beneficial effects of estrogen on HDL elevation. (81) This was also found in an earlier study comparingprogesterone with both nortestosterone and MPA. (82)

Third generation progestins, such as norgestimate and desogestrel, have not demonstrated thissame adverse effect on serum lipids. (83)

MPA increases the extent of atherosclerosisin coronary arteries, suppresses the protective effect of estrogen on arterial injury, increases insulinresistance, and attenuates the beneficial effects ofestrogen on vasodilation. (84-86) This is consistent withfindings that synthetic estrogen as well as 19-nortestosterone can result in a decrease in glucose tolerance, whereas glucose metabolism is unaffected byP4. (87) Progesterone has furthermore been shown tohave an antiproliferative effect on vascular smoothmuscle in normal human and animal tissues as wellas in models simulating hyperinsulinemia and hyperglycemia. (88,89)

In two studies comparing E2 and P4 with E2and MPA, E2 and P4 protected against coronary hyper-reactivity and subsequent coronary vasospasm,whereas coronary vasospasm was increased in monkeys receiving MPA. (90,91) In a separate study, the sameauthors demonstrated an inhibition of coronary vasospasm with topical progesterone cream in pre-atherosclerotic primates. (92)

One study comparing MPA to progesteronedemonstrated progesterone reduced the risk for arteriosclerosis by inhibiting vascular cell adhesionmolecule-1 (VCAM-1), whereas MPA did not. (93) Thediffering effects of progesterone and MPA supportprogesterone as a better option.

Progesterone and 17beta-estradiol both inhibited cardiac fibroblast growth, with the effectsof 17beta-estradiol enhanced by P4, suggesting thecombination may help protect postmenopausal women against cardiovascular disease. (94)

Normal liver function is essential for lipidmetabolism. Synthetic progestins retain undesirableeffects on liver metabolism, even when administeredthrough the skin. (83) In regard to estrogen, a comparison between orally administered ethinyl estradiol(EE) and E2 demonstrated beneficial effects on serumlipids (EE>E2); however, EE demonstrated a markedincrease in liver protein synthesis, including sex-hormone binding globulin (SHBG) and pregnancy zoneprotein (PZP), markers of increased estrogenic effect. (95) SHBG elevation can result in lower testosterone activity due to its greater affinity to testosteroneand dihydrotestosterone than estrogen.

Natural progesterone, in either oral, vaginal,or topical administrations, has demonstrated safety inits effects on lipid metabolism and blood clotting. (77,80,96) The research to date looking at cardiovascular riskpoints to bioidentical hormones, particularly progesterone, as the hormone therapy of choice to supporthealthy vascular function.

The Effect of Hormones on the Breast

In the past, the effect of synthetic progestinson the breast was unclear. Whereas progestins havebeen used historically to treat some forms of advancedbreast cancer, a re-evaluation of results of a cohortstudy suggest an increased risk in the occurrence ofbreast cancer in women using combined HRT (predominantly CEE plus MPA) beyond that seen withunopposed estrogen; the risk increase, however, wasnot statistically significant. (97) Recently, the effect ofHRT on breast tissue was demonstrated in the WHIstudy. A 26-percent increased risk of invasive breastcancer was seen in women using a combination ofCEE and MPA compared to placebo. (4)

Several reviews suggest a protective effectof progesterone and some progestins on normal andpathological breast tissue, including a strong anti-proliferative effect both in the presence and absence ofestrogens. (98-102) Low endogenous progesterone levelswere also correlated with a five-fold increase in premenopausal breast cancer risk in women experiencing infertility when compared with infertile womenwith normal hormone levels. (103) In women undergoing breast surgery for benign breast conditions, pretreatment with topical estrogen resulted in increasedepithelial proliferation compared to a reduction inproliferation seen with percutaneous progesteronetreatment; furthermore, progesterone reduced estrogen-induced proliferation when both treatments wereused. (104) An in vitro study evaluating the effect ofprogesterone on the growth of T47-D breast cancercells demonstrated increased apoptosis as mediatedby the regulation of genes controlling apoptosis. (105) Ina review by Desreux et al, the authors emphasizedprogesterone’s role in supporting healthy breast homeostasis. (106) Progesterone opposes the proliferativeeffects of estradiol in the breast, (106,107) a role not seenwith synthetic progestins. (106)

A large cohort study involving 1,150 Frenchwomen with benign breast disease showed no increase in breast cancer risk with women using topical progesterone cream (RR=0.8), a common European treatment for breast mastalgia. Furthermore,the researchers noted a decrease in breast cancer riskamong women using progesterone cream plus an oralprogestogen (RR=0.5), compared with women usingoral progestogens alone. (108)

Two recent studies point to a difference inbreast cancer risk when comparing synthetic progestins to bioidentical progesterone as a part of theHRT regimen. A French cohort study involving 3,175postmenopausal women predominantly using naturalHRT (83 percent using transdermal estradiol and anon-MPA progestogen – progesterone and others)found no increased risk in users of these forms ofHRT.109The French E3N-EPIC cohort study is probably the most significant examination of the differences between progestogens and breast cancer risk.It assessed the risk of breast cancer associated withHRT use in 54,548 postmenopausal women and foundthe risk was significantly greater (p<0.001) with HRTcontaining synthetic progestins (RR=1.4 [1.2-1.7])than with HRT containing micronized progesterone(RR=0.9 [0.7-1.2]). (110) Although there are no prospective trials looking at the safety of bioidenticalprogesterone with respect to the breast, these largecohort studies, in combination with studies examining the effects of progesterone on normal and cancerous breast cells, do provide enticing evidence for thesafety of bioidentical progesterone.

It is well understood that, due to proliferativeeffect on normal breast cells as well as on numerousbreast cancer cell lines, estrogens are contraindicatedfor women at risk for breast cancer, because, as referenced above, increased estrone and estradiol levelsare associated with an increased risk of breast cancer.The supplementation of either of these forms of estrogen increases serum estradiol and estrone due tothe pathways by which they are metabolized. In contrast, several studies have demonstrated an inverserelationship between estriol levels and breast canceras well as antitumor effects of estriol. (27, 111-113) However, while there is reason to believe that estriol inlow doses could be protective for the breast in someindividuals, when supplementing estrogens, one mustalso consider the differences among individuals withrespect to metabolism. A recent study looking at theeffects of 14 different endogenous estrogen metabolites demonstrated proliferative, antiproliferative, andbi-phasic effects on a specific human breast cancerline (MCF-7), further emphasizing the importance ofindividualized consideration. (114)

The Effect of Hormones on theEndometrium

Both OMP and vaginal delivery of progesterone result in sufficient end-organ effect on the uteruswith doses beginning at 100 mg daily x 25 days/month or 45 mg every other day for six doses/month,respectively. (83,115,116) Similar end-organ results havebeen seen using percutaneous progesterone cream. (117)

Hormones and Menopausal Symptoms

Although most physicians attribute vasomotor flushing to a lack of estrogen, progestogens canhave a beneficial effect. (118) A study using a progesterone cream applied to the skin resulted in a significantreduction in the number and intensity of hot flashes in83 percent of the study participants, as well as benefits in other quality-of-life measurements.(119) In a separate study, subjects receiving 20 mg of topical progesterone cream daily for four weeks demonstratedsignificant improvement of menopausal symptoms,measured by Greene Climacteric Scale scores. (77)

In a study comparing the effects of CEE plusMPA to CEE plus OMP in postmenopausal women,the latter group had significantly improved sleep efficiency over the synthetic progestin group. (120) Anotherstudy comparing MPA to OMP found micronizedprogesterone to be better tolerated than MPA, as wellas conferring additional benefits in cognition and improvement of menstrual problems. (121)

Oral and transdermal estradiol preparations have been found to confer benefit for menopausal symptoms and vaginal cytology, as well asreduce bone loss in postmenopausal women. (53,55) Estriol has also been demonstrated to reverse vaginalatrophy. (122,123) Estriol doses must be increased up tothree times the dose of estradiol to achieve similareffects (e.g., reducing hot flashes and vaginal drynessin menopausal women) and is typically dosed twicedaily to achieve steady blood levels. (27)

Hormones and Bone Health

Bone turnover increases at menopause andmay remain high for 25 or more years following thelast menstrual cycle. (124) Hormonal control of boneturnover is not limited to a single hormone, but ratherthe complex interrelationship of a number of steroidand other hormones, including estrogen, progesterone, testosterone, corticosteroids, vitamin D, thyroidhormones, and retinoids. (125) When given alone, estrogens have a known beneficial effect on limiting boneloss as well as reducing the number of fractures. Studies with progesterone alone are mixed. Progesteronesupports bone health through its effects on the proliferation and differentiation of human osteoblasts. (126) Several animal and human studies have demonstratedprogesterone’s positive effect on bone formation aswell as inhibition of bone resorption.(127-130) However,double-blind placebo-controlled studies in humanshave yet to demonstrate a significant increase in bonemineral density (BMD) or a reduction in fracturerate with progesterone alone. One short-term humanstudy of OMP showed no difference in markers ofbone resorption compared to placebo.(131) Longer-termstudies evaluating BMD and fracture rate are neededto determine the value of progesterone supplementation alone for preventing or treating osteoporosis.Several studies looking at estrogen and progesteronesupplementation suggest estrogen and progesteronehave distinct and complementary roles in the maintenance of bone.(46,130,132) Testosterone can also decreaseurinary calcium loss and bone resorption.(76,133)

Hormones and the Brain

Progesterone has numerous beneficial effectson the brain and nervous system, including supporting myelin formation and activating GABA receptors.(134) Progesterone also plays a role in the reductionof ischemia in the brain and decreasing the inflammatory response after traumatic brain injury.(135,136) Areview of progesterone’s effect on the brain suggestsviable therapeutic possibilities for the prevention andtreatment of neurodegenerative diseases, as well asfor repair processes and preservation of cognitivefunction with age. (137) Synthetic progestins do not sharethese physiological effects. In fact, the WHIMS foundequine estrogen plus synthetic progestins (PremPro)doubled the risk of developing dementia in womenage 65 and older. (12)

Estrogens have known physiological effectson the brain, including improved blood flow via vasodilation and stimulation of serotonin and norepinephrine, which can impact nerve cell function and mood.It was postulated that estrogen could help delay age-related cognitive decline or help prevent Alzheimer’s disease, and small studies on animals appearedto confirm this.138However, two large-scale humanstudies failed to demonstrate any significant benefitof estrogen supplementation on cognitive function.

The Atherosclerosis Risk in Communities(ARIC) study evaluated the effects of estrogen onmemory and cognitive function in 2,000 women participants ages 48-67 over a 10-year period and foundno correlation (either positive or negative) betweenestrogen and cognitive function.138

The WHIMS also failed to demonstrate acognitive benefit for estrogen alone. In fact, resultsdemonstrated an increased risk for dementia in women using estrogen alone, although not as great a riskas combined synthetic HRT.12It should be noted thatthe WHIMS utilized equine estrogens with or without MPA, while the prospective ARIC study did not denote estrogens utilized.

Conclusion

The use of bioidentical hormone therapy iswell tolerated, provides symptom relief, and can address many of the health needs as well as the individual preferences of menopausal and perimenopausalwomen. Physicians are encouraged to take the timeand effort to help women determine the regimen thatbest suits their needs, including testing hormone levels directly prior to supplementation and using theleast amount necessary to achieve the desired results.This effort will undoubtedly pay off in fewer unwanted side effects and greater quality of life.

References

1. Wetzel W. Human identical hormones: real people,real problems, real solutions. Nurse Pract Forum1998;9:227-334.

2. Andrist LC. The impact of media attention, familyhistory, politics and maturation on women’sdecisions regarding hormone replacement therapy.Health Care Women Int 1998;19:243-260.

3. Hunter MS, O’Dea I, Britten N. Decision-makingand hormone replacement therapy: a qualitativeanalysis. Soc Sci Med 1997;45:1541-1548.

4. Rossouw JE, Anderson GL, Prentice RL, et al.Risks and benefits of estrogen plus progestin inhealthy postmenopausal women: principal resultsFrom the Women’s Health Initiative randomizedcontrolled trial. JAMA 2002;288:321-333.

5. Johannes CB, Crawford SL. Menstrual bleeding,hormones, and the menopausal transition. SeminReprod Endocrinol 1999;17:299-309.

6. Richardson SJ. The biological basis of themenopause. Baillieres Clin Endocrinol Metab1993;7:1-16.

7. Burger HG. The endocrinology of the menopause. JSteroid Biochem Mol Biol 1999;69:31-35.

8. Klein NA, Soules MR. Endocrine changes of theperimenopause. Clin Obstet Gynecol 1998;41:912-920.

9. Burger HG. Diagnostic role of folliclestimulating hormone (FSH) measurementsduring the menopausal transition – an analysisof FSH, oestradiol and inhibin. Eur J Endocrinol1994;130:38-42.

10. Burger HG. The endocrinology of the menopause.Maturitas 1996;23:129-136.

11. Speroff L, Glass RH, Kase NG. ClinicalGynecologic Endocrinology and Infertility. 6th ed.Philadelphia, PA: Lippincott, Williams & Wilkins;1999.

12. Shumaker SA, Legault C, Rapp SR, et al. Estrogenplus progestin and the incidence of dementia andmild cognitive impairment in postmenopausalwomen: the Women’s Health Initiative MemoryStudy: a randomized controlled trial. JAMA2003;289:2651-2662.

13. Vihtamaki T, Savilahti R, Tuimala R. Why dopostmenopausal women discontinue hormonereplacement therapy? Maturitas 1999;33:99-105.

14. Newton KM, LaCroix AZ, Leveille SG, et al.Women’s beliefs and decisions about hormonereplacement therapy. J Womens Health 1997;6:459-465.

15. Legare F, Godin G, Guilbert E, et al. Determinantsof the intention to adopt hormone replacementtherapy among premenopausal women. Maturitas2000;34:211-218.

16. den Tonkelaar I, Oddens BJ. Determinants of longterm hormone replacement therapy and reasons forearly discontinuation. Obstet Gynecol 2000;95:507-512.

17. Ettinger B, Pressman A. Continuation ofpostmenopausal hormone replacement therapy in alarge health maintenance organization: transdermalmatrix patch versus oral estrogen therapy. Am JManag Care 1999;5:779-785.

18. Bjorn N, Backstrom T. Compliance to HRT: thesignificance of negative side effects and moodsymptoms. Abstract: Eighth Annual Meeting ofNAMS. Menopause 1997;4:283.

19. Ettinger B, Pressman A, Silver P. Effect of ageon reasons for initiation and discontinuationof hormone replacement therapy. Menopause1999;6:282-289.

20. Perrone G, Capri O, Borrello M, Galoppi P.Attitudes toward estrogen replacement therapy.Study conducted on a sample population ofwomen attending an ambulatory care center forthe treatment of menopause. Minerva Ginecol1993;45:603-608. [Article in Italian]

21. Leake R. Contents of HRT and mechanismsof action. J Epidemiol Biostat 1999;4:129-133;discussion 133-139.

22. Huber JC, Campagnoli C, Druckmann R, et al.Recommendations for estrogen and progestinreplacement in the climacteric and postmenopause.European Progestin Club. Maturitas 1999;33:197-209.

23. Kabuto M, Akiba S, Stevens RG, et al. Aprospective study of estradiol and breast cancer inJapanese women. Cancer Epidemiol BiomarkersPrev 2000;9:575-579.

24. Miyoshi Y, Tanji Y, Taguchi T, et al. Association ofserum estrone levels with estrogen receptor-positivebreast cancer risk in postmenopausal Japanesewomen. Clin Cancer Res 2003;9:2229-2233.

25. Ursin G, Palla SL, Reboussin BA, et al. Posttreatment change in serum estrone predictsmammographic percent density changes inwomen who received combination estrogenand progestin in the postmenopausal estrogen/progestin interventions (PEPI) trial. J Clin Oncol2004;22:2842-2848.

26. van der Vies J. The pharmacology of oestriol.Maturitas 1982;4:291-299.

27. Follingstad AH. Estriol, the forgotten estrogen?JAMA 1978;239:29-30.

28. Head KA. Estriol: safety and efficacy. Altern MedRev 1998;3:101-113.

29. Mashchak CA, Lobo RA, Dozono-Takano R, etal. Comparison of pharmacodynamic propertiesof various estrogen formulations. Am J ObstetGynecol 1982;144:511-518.

30. http://www.pharmafocus.com/cda/focusH/1,2109,21-0-0-JUN_2004-focus_news_detail-0-225648,00.html [Accessed July 26, 2006]

31. Hudson T. Wild yam, natural progesterone:unraveling the mystery. The Townsend Letter forDoctors and Patients 1996;July:156.

32. Hirvonen E. Progestins. Maturitas 1996;23:S13-S18.

33. Gompel A. Progestin treatments of menopause. RevPrat 1993;43:2645-2650. [Article in French]

34. Belaisch J. Chemical classification of syntheticprogestogens. Rev Fr Gynecol Obstet 1985;80:473-477. [Article in French]

35. Fuhrmann U, Krattenmacher R, Slater EP,Fritzemeier KH. The novel progestin drospirenoneand its natural counterpart progesterone:biochemical profile and antiandrogenic potential.Contraception 1996;54:243-251.

36. Ojasoo T. Multivariate preclinical evaluation ofprogestins. Menopause J North Am Menopause Soc1995;2:97-107.

37. Kamada M, Irahara M, Aono T. Action of syntheticprogestin. Nippon Rinsho 1994;52:593-599.[Article in Japanese]

38. Jordan VC, Jeng MH, Catherino WH, Parker CJ.The estrogenic activity of synthetic progestins usedin oral contraceptives. Cancer 1993;71:1501-1505.

39. Negro-Vilar A. New progestins and potentialactions. J Soc Gynecol Investig 2000;7:S53-S54.

40. http://www.acog.org/from_home/publications/press_releases/nr10-01-04.cfm [Accessed July 26,2006]

41. Chambon Y. Synergism and antagonism betweenestrogens and progestins: an update. Bull Acad NatlMed 1993;177:177-186. [Article in French]

42. Hargrove JT, Osteen KG. An alternative methodof hormone replacement therapy using the naturalsex steroids. Infertility Reprod Med Clin North Am1995;6:653-674.

43. Saffran J, Loeser BK, Faber LE. Effects ofprogestins on the progesterone receptor in guineapig uterus. Adv Exp Med Biol 1979;117:223-239.

44. Cato AC, Ponta H. Different regions of the estrogenreceptor are required for synergistic action withthe glucocorticoid and progesterone receptors. MolCell Biol 1989;9:5324-5330.

45. Bradshaw MS, Tsai SY, Leng XH, et al. Studies onthe mechanism of functional cooperativity betweenprogesterone and estrogen receptors. J Biol Chem1991;266:16684-16690.

46. Schmidt IU, Wakley GK, Turner RT. Effectsof estrogen and progesterone on tibiahistomorphometry in growing rats. Calcif Tissue Int2000;67:47-52.

47. Casper RF. Estrogen with interrupted progestinHRT: a review of experimental and clinical studies.Maturitas 2000;34:97-108.

48. Casper RF, MacLusky NJ, Vanin C, Brown TJ.Rationale for estrogen with interrupted progestin asa new low-dose hormonal replacement therapy. JSoc Gynecol Investig 1996;3:225-234.

49. DeSombre ER, Kuivanen PC. Progestin modulationof estrogen-dependent marker protein synthesis inthe endometrium. Semin Oncol 1985;12:6-11.

50. http://www.fda.gov/bbs/topics/NEWS/2003/NEW00938.html [Accessed July 26, 2006]

51. Nahoul K, Dehennin L, Jondet M, Roger M.Profiles of plasma estrogens, progesterone and theirmetabolites after oral or vaginal administration ofestradiol or progesterone. Maturitas 1993;16:185-202.

52. Lyrenas S, Carlstrom K, Backstrom T, von SchoultzB. A comparison of serum oestrogen levels afterpercutaneous and oral administration of oestradiol-17 beta. Br J Obstet Gynaecol 1981;88:181-187.

53. Selby P, McGarrigle HH, Peacock M. Comparisonof the effects of oral and transdermal oestradioladministration on oestrogen metabolism, proteinsynthesis, gonadotrophin release, bone turnover andclimacteric symptoms in postmenopausal women.Clin Endocrinol (Oxf) 1989;30:241-249.

54. Palacios S, Menendez C, Jurado AR, Vargas JC.Effects of oestradiol administration via differentroutes on the lipid profile in women with bilateraloophorectomy. Maturitas 1994;18:239-244.

55. Pattison NS, Uptin T, Knox B, France J.Transdermal oestrogen for postmenopausal women:a double blind crossover comparative study withethinyl oestradiol. Aust N Z J Obstet Gynaecol1989;29:62-65.

56. Warren MP, Shantha S. Uses of progesteronein clinical practice. Int J Fertil Womens Med1999;44:96-103.

57. de Lignieres B, Dennerstein L, BackstromT. Influence of route of administration onprogesterone metabolism. Maturitas 1995;21:251-257.

58. Hermann AC, Nafziger AN, Victory J, et al.Over-the-counter progesterone cream producessignificant drug exposure compared to a food anddrug administration-approved oral progesteroneproduct. J Clin Pharmacol 2005;45:614-619.

59. Pouly JL, Bassil S, Frydman R, et al. Luteal phasesupport after vaginal progesterone: comparativestudy with micronized oral progesterone.Contracept Fertil Sex 1997;25:596-601. [Article inFrench]

60. Mahesh VB, Brann DW, Hendry LB. Diversemodes of action of progesterone and itsmetabolites. J Steroid Biochem Mol Biol1996;56:209-219.

61. Dusterberg B, Nishino Y. Pharmacokinetic andpharmacological features of oestradiol valerate.Maturitas 1982;4:315-324.

62. McAuley JW, Kroboth FJ, Kroboth PD. Oraladministration of micronized progesterone: areview and more experience. Pharmacotherapy1996;16:453-457.

63. Burry KA, Patton PE, Hermsmeyer K.Percutaneous absorption of progesterone inpostmenopausal women treated with transdermalestrogen. Am J Obstet Gynecol 1999;180:1504-1511.

64. Mircioiu C, Perju A, Griu E, et al.Pharmacokinetics of progesterone inpostmenopausal women: 2. Pharmacokineticsfollowing percutaneous administration. Eur J DrugMetab Pharmacokinet 1998;23:397-402.

65. Mircioiu C, Perju A, Neagu A, et al.Pharmacokinetics of progesterone inpostmenopausal women: 1. Pharmacokineticsfollowing intravaginal administration. Eur J DrugMetab Pharmacokinet 1998;23:391-396.

66. Cicinelli E, Nahoul K, Sabatelli S, et al.Administration of unmodified progesterone bynasal spray in fertile women. Gynecol Endocrinol1995;9:289-293.67. Levy T, Gurevitch S, Bar-Hava I, et al.Pharmacokinetics of natural progesteroneadministered in the form of a vaginal tablet. HumReprod 1999;14:606-610.

68. Rylance PB, Brincat M, Lafferty K, et al. Naturalprogesterone and antihypertensive action. Br Med J(Clin Res Ed) 1985;290:13-14.

69. Armstrong JG. Hypotensive action of progesteronein experimental and human hypertension. Proc SocExp Biol Med 1959;102:452-455.

70. Oelkers WK. Effects of estrogens and progestogenson the renin-aldosterone system and blood pressure.Steroids 1996;61:166-171.

71. Elkik F, Mauvais-Jarvis P. The role of progesteroneand progestins in hydroelectrolytic metabolism(author’s transl). Nouv Presse Med 1980;9:35-38.[Article in French]

72. Tollan A, Oian P, Kjeldsen SE, et al. Progesteronereduces sympathetic tone without changing bloodpressure or fluid balance in men. Gynecol ObstetInvest 1993;36:234-238.

73. Molinari C, Battaglia A, Grossini E, et al. Effectof progesterone on peripheral blood flow inprepubertal female anesthetized pigs. J Vasc Res2001;38:569-577.

74. Tsuda K, Kinoshita Y, Nishio I. Synergistic role ofprogesterone and nitric oxide in the regulation ofmembrane fluidity of erythrocytes in humans: anelectron paramagnetic resonance investigation. AmJ Hypertens 2002;15:702-708.

75. Toy JL, Davies JA, Hancock KW, McNicol GP. Thecomparative effects of a synthetic and a ‘natural’oestrogen on the haemostatic mechanism in patientswith primary amenorrhoea. Br J Obstet Gynaecol1978;85:359-362.

76. Orwoll ES, Stribrska L, Ramsey EE, Keenan EJ.Androgen receptors in osteoblast-like cell lines.Calcif Tissue Int 1991;49:183-187.

77. Stephenson K, Price C, Kurdowska A, et al.Progesterone cream does not increase thromboticand inflammatory factors in postmenopausalwomen. Blood 2004;104:16.

78. Cheng W, Lau OD, Abumrad NA. Twoantiatherogenic effects of progesterone onhuman macrophages; inhibition of cholesterylester synthesis and block of its enhancementby glucocorticoids. J Clin Endocrinol Metab1999;84:265-271.

79. Fahraeus L, Larsson-Cohn U, Wallentin L.L-norgestrel and progesterone have differentinfluences on plasma lipoproteins. Eur J Clin Invest1983;13:447-453.

80. Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Effects of natural andsynthetic hormones on subfractions of HDLcholesterol and liver proteins. Acta Obstet GynecolScand Suppl 1984;127:1-37.

81. No authors listed. Effects of estrogen or estrogen/progestin regimens on heart disease risk factorsin postmenopausal women. The PostmenopausalEstrogen/Progestin Interventions (PEPI) Trial.The Writing Group for the PEPI Trial. JAMA1995;273:199-208.

82. Ottosson UB, Johansson BG, von Schoultz B.Subfractions of high-density lipoprotein cholesterolduring estrogen replacement therapy: a comparisonbetween progestogens and natural progesterone.Am J Obstet Gynecol 1985;151:746-750.

83. Warren MP, Biller BM, Shangold MM. A newclinical option for hormone replacement therapyin women with secondary amenorrhea: effectsof cyclic administration of progesterone fromthe sustained-release vaginal gel Crinone (4%and 8%) on endometrial morphologic featuresand withdrawal bleeding. Am J Obstet Gynecol1999;180:42-48.

84. Williams JK, Honore EK, Washburn SA, ClarksonTB. Effects of hormone replacement therapy onreactivity of atherosclerotic coronary arteriesin cynomolgus monkeys. J Am Coll Cardiol1994;24:1757-1761.

85. Wagner JD, Martino MA, Jayo MJ, et al. Theeffects of hormone replacement therapy oncarbohydrate metabolism and cardiovascular riskfactors in surgically postmenopausal cynomolgusmonkeys. Metabolism 1996;45:1254-1262.

86. Wallace JM, Shively CA, Clarkson TB. Effects ofhormone replacement therapy and social stress onbody fat distribution in surgically postmenopausalmonkeys. Int J Obes Relat Metab Disord1999;23:518-527.

87. Beck P. Effect of progestins on glucose and lipidmetabolism. Ann N Y Acad Sci 1977;286:434-445.

88. Carmody BJ, Arora S, Wakefield MC, et al.Progesterone inhibits human infragenicular arterialsmooth muscle cell proliferation induced by highglucose and insulin concentrations. J Vasc Surg2002;36:833-838.

89. Lee WS, Harder JA, Yoshizumi M, et al.Progesterone inhibits arterial smooth muscle cellproliferation. Nat Med 1997;3:1005-1008.

90. Minshall RD, Stanczyk FZ, Miyagawa K, etal. Ovarian steroid protection against coronaryartery hyperreactivity in rhesus monkeys. J ClinEndocrinol Metab 1998;83:649-659.

91. Miyagawa K, Rosch J, Stanczyk F, HermsmeyerK. Medroxyprogesterone interferes with ovariansteroid protection against coronary vasospasm. NatMed 1997;3:324-327.

92. Hermsmeyer RK, Mishra RG, Pavcnik D, etal. Prevention of coronary hyperreactivity inpreatherogenic menopausal rhesus monkeys bytransdermal progesterone. Arterioscler ThrombVasc Biol 2004;24:955-961.

93. Otsuki M, Saito H, Xu X, et al. Progesterone, butnot medroxyprogesterone, inhibits vascular celladhesion molecule-1 expression in human vascularendothelial cells. Arterioscler Thromb Vasc Biol2001;21:243-248.

94. Dubey RK, Gillespie DG, Jackson EK, Keller PJ.17Beta-estradiol, its metabolites, and progesteroneinhibit cardiac fibroblast growth. Hypertension1998;31:522-528.

95. Ottosson UB, Carlstrom K, Johansson BG, vonSchoultz B. Estrogen induction of liver proteins andhigh-density lipoprotein cholesterol: comparisonbetween estradiol valerate and ethinyl estradiol.Gynecol Obstet Invest 1986;22:198-205.

96. Suvanto-Luukkonen E, Sundstrom H, PenttinenJ, Kauppila A. Lipid effects of an intrauterinelevonorgestrel device or oral vs. vaginal naturalprogesterone in post-menopausal women treatedwith percutaneous estradiol. Arch Gynecol Obstet1998;261:201-208.

97. Schairer C, Lubin J, Troisi R, et al. Menopausalestrogen and estrogen-progestin replacementtherapy and breast cancer risk. JAMA2000;283:485-491.

98. Mauvais-Jarvis P, Kuttenn F, Gompel A,Benotmane A. Antiestrogen action of progesteronein the breast. Pathol Biol (Paris) 1987;35:1081-1086. [Article in French]

99. Mauvais-Jarvis P, Kuttenn F, Gompel A. Estradiol/progesterone interaction in normal and pathologicbreast cells. Ann N Y Acad Sci 1986;464:152-167.

100. Gorins A, Denis C. Effects of progesterone andprogestational hormones on the mammary gland.Arch Anat Cytol Pathol 1995;43:28-35. [Article inFrench]

101. Inoh A, Kamiya K, Fujii Y, Yokoro K. Protectiveeffects of progesterone and tamoxifen inestrogen-induced mammary carcinogenesis inovariectomized W/Fu rats. Jpn J Cancer Res1985;76:699-704.

102. Wren BG, Eden JA. Do progestogens reduce therisk of breast cancer? A review of the evidence.Menopause J North Am Menopause Soc 1996;3:4-12.

103. Cowan LD, Gordis L, Tonascia JA, Jones GS.Breast cancer incidence in women with a historyof progesterone deficiency. Am J Epidemiol1981;114:209-217.

104. Chang KJ, Lee TT, Linares-Cruz G, et al.Influences of percutaneous administration ofestradiol and progesterone on human breastepithelial cell cycle in vivo. Fertil Steril1995;63:785-791.

105. Formby B, Wiley TS. Progesterone inhibits growthand induces apoptosis in breast cancer cells:inverse effects on Bcl-2 and p53. Ann Clin Lab Sci1998;28:360-369.

106. Desreux J, Kebers F, Noel A, et al. Progesteronereceptor activation – an alternative to SERMs inbreast cancer. Eur J Cancer 2000;36:S90-S91.

107. Malet C, Spritzer P, Guillaumin D, Kuttenn F.Progesterone effect on cell growth, ultrastructuralaspect and estradiol receptors of normal humanbreast epithelial (HBE) cells in culture. J SteroidBiochem Mol Biol 2000;73:171-181.

108. Plu-Bureau G, Le MG, Thalabard JC, et al.Percutaneous progesterone use and risk of breastcancer: results from a French cohort study ofpremenopausal women with benign breast disease.Cancer Detect Prev 1999;23:290-296.

109. de Lignieres B, de Vathaire F, Fournier S, et al.Combined hormone replacement therapy and riskof breast cancer in a French cohort study of 3175women. Climacteric 2002;5:332-340.

110. Fournier A, Berrino F, Riboli E, et al. Breast cancerrisk in relation to different types of hormonereplacement therapy in the E3N-EPIC cohort. Int JCancer 2005;114:448-454.

111. Lemon HM, Wotiz HH, Parsons L, MozdenPJ. Reduced estriol excretion in patients withbreast cancer prior to endocrine therapy. JAMA1966;196:1128-1136.

112. Lemon HM. Pathophysiologic considerations in thetreatment of menopausal patients with oestrogens;the role of oestriol in the prevention of mammarycarcinoma. Acta Endocrinol Suppl (Copenh)1980;233:17-27.

113. Lemon HM. Estriol prevention ofmammary carcinoma induced by 7,12-dimethylbenzanthracene and procarbazine. CancerRes 1975;35:1341-1353.

114. Lippert C, Seeger H, Mueck AO. The effectof endogenous estradiol metabolites on theproliferation of human breast cancer cells. Life Sci2003;72:877-883.

115. de Lignieres B. Oral micronized progesterone. ClinTher 1999;21:41-60;discussion 1-2.

116. Sitruk-Ware R, Bricaire C, De Lignieres B, et al.Oral micronized progesterone. Bioavailabilitypharmacokinetics, pharmacological andtherapeutic implications – a review. Contraception1987;36:373-402.

117. Wilson KJ. Private communication.

118. Schiff I. The effects of progestins on vasomotorflushes. J Reprod Med 1982;27:498-502.

119. Leonetti HB, Longo S, Anasti JN. Transdermalprogesterone cream for vasomotor symptomsand postmenopausal bone loss. Obstet Gynecol1999;94:225-228.

120. Montplaisir J, Lorrain J, Denesle R, Petit D. Sleepin menopause: differential effects of two formsof hormone replacement therapy. Menopause2001;8:10-16.

121. Ryan N, Rosner A. Quality of life and costsassociated with micronized progesterone andmedroxyprogesterone acetate in hormonereplacement therapy for nonhysterectomized,postmenopausal women. Clin Ther 2001;23:1099-1115.

122. van der Linden MC, Gerretsen G, Brandhorst MS,et al. The effect of estriol on the cytology of urethraand vagina in postmenopausal women with genitourinary symptoms. Eur J Obstet Gynecol ReprodBiol 1993;51:29-33.

123. Heimer GM. Estriol in the postmenopause. ActaObstet Gynecol Scand Suppl 1987;139:1-23.

124. Takahashi M, Kushida K, Hoshino H, et al.Biochemical markers of bone turnover do notdecline after menopause in healthy women. Br JObstet Gynaecol 1999;106:427-431.

125. Bland R. Steroid hormone receptor expression andaction in bone. Clin Sci (Lond) 2000;98:217-240.

126. Liang M, Liao EY, Xu X, et al. Effects ofprogesterone and 18-methyl levonorgestrel onosteoblastic cells. Endocr Res 2003;29:483-501.

127. Barengolts EI, Gajardo HF, Rosol TJ, et al. Effectsof progesterone on postovariectomy bone loss inaged rats. J Bone Miner Res 1990;5:1143-1147.

128. Bowman BM, Miller SC. Elevated progesteroneduring pseudopregnancy may prevent bone lossassociated with low estrogen. J Bone Miner Res1996;11:15-21.

129. Fujimaki T, Kurabayashi T, Yamamoto Y, et al.Effects of progesterone on the metabolism ofcancellous bone in young oophorectomized rats. JObstet Gynaecol 1995;21:31-36.

130. Burnett CC, Reddi AH. Influence of estrogen andprogesterone on matrix-induced endochondral boneformation. Calcif Tissue Int 1983;35:609-614.

131. Ikram Z, Dulipsingh L, Prestwood KM. Lackof effect of short-term micronized progesteroneon bone turnover in postmenopausal women. JWomens Health Gend Based Med 1999;8:973-978.

132. Yamamoto Y, Kurabayashi T, Tojo Y, et al. Effectsof progestins on the metabolism of cancellous bonein aged oophorectomized rats. Bone 1998;22:533-537.

133. Wang C, Eyre DR, Clark R, et al. Sublingualtestosterone replacement improves muscle massand strength, decreases bone resorption, andincreases bone formation markers in hypogonadalmen – a clinical research center study. J ClinEndocrinol Metab 1996;81:3654-3662.

134. Baulieu E, Schumacher M. Progesterone as aneuroactive neurosteroid, with special reference tothe effect of progesterone on myelination. Steroids2000;65:605-612.

135. Gibson CL, Murphy SP. Progesterone enhancesfunctional recovery after middle cerebral arteryocclusion in male mice. J Cereb Blood Flow Metab2004;24:805-813.

136. Grossman KJ, Goss CW, Stein DG. Effects ofprogesterone on the inflammatory response to braininjury in the rat. Brain Res 2004;1008:29-39.

137. Schumacher M, Guennoun R, Robert F, et al. Localsynthesis and dual actions of progesterone in thenervous system: neuroprotection and myelination.Growth Horm IGF Res 2004;14:S18-S33.

138. de Moraes SA, Szklo M, Knopman D, Park E.Prospective assessment of estrogen replacementtherapy and cognitive functioning: atherosclerosisrisk in communities study. Am J Epidemiol2001;154:733-739.

Source:Altern Med Rev.2006 Sep;11(3):208-23.

This post has not been tagged.

Share |
Permalink | Comments (0)
 
Community Search
Sign In


Forgot your password?

Haven't registered yet?

Calendar

9/14/2017 » 9/16/2017
ACAM 2017 Annual Meeting

Latest News